MATRIX ENGINEERING

被引:65
作者
BALAZS, EA [1 ]
BLAND, PA [1 ]
DENLINGER, JL [1 ]
GOLDMAN, AI [1 ]
LARSEN, NE [1 ]
LESHCHINER, EA [1 ]
LESHCHINER, A [1 ]
MORALES, B [1 ]
机构
[1] BIOMATRIX INC, RIDGEFIELD, NJ 07657 USA
关键词
HYALURONAN; HYALURONIC ACID; (HA); HYLAN; VISCOSURGERY; VISCOELASTIC; LEECH;
D O I
10.1097/00001721-199102000-00026
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Matrix engineering is a technology that utilizes hyaluronan (HA, hyaluronic acid) based matrices to control, direct or augment tissue regenerative processes. Hyaluronan and the concept of matrix engineering have become established tools in ophthalmic and orthopaedic medicine. The clinical indications for HA are limited by the physical properties and short residence time of the natural HA molecule. To expand and improve upon its current medical applications, a family of HA derivatives was prepared by chemical modification and cross-linking. Relative to the non-modified HA molecule, the hylan family of polymers provides more versatile physical forms, improved mechanical properties and an extended residence time. Hylan can also be used as a surface coating to improve blood compatibility. The chemical, physical and biological properties of hylans will be reviewed, focusing on the specific therapeutic indications they enable.
引用
收藏
页码:173 / 178
页数:6
相关论文
共 56 条
  • [1] ALGEVERE P, ACTA OPHTHALMOL, V49, P975
  • [2] Balazs E A, 1972, Mod Probl Ophthalmol, V10, P3
  • [3] Balazs E.A., 1974, DISORDERS KNEE, V2, P63
  • [4] Balazs E.A., 1979, US Patent, Patent No. [#4,141,973, 4141973]
  • [5] BALAZS EA, 1989, CIBA F SYMP, V143, P265
  • [6] NOMENCLATURE OF HYALURONIC-ACID
    BALAZS, EA
    LAURENT, TC
    JEANLOZ, RW
    [J]. BIOCHEMICAL JOURNAL, 1986, 235 (03) : 903 - 903
  • [7] BALAZS EA, 1971, HYALURONIC ACID MATR, P131
  • [8] Balazs EA, 1986, U. S. Patent, Patent No. [4,582,865, 4582865]
  • [9] Balazs EA, 1985, J EQUINE VET, V5, P217, DOI DOI 10.1016/S0737
  • [10] BALAZS EA, 1988, P INT C CELLULOSICS